These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8040114)

  • 1. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activity of cefpodoxime against pathogens causing respiratory, urinary or soft tissue infections].
    Silva F; Durán C; Ulloa MT; Prado V
    Rev Med Chil; 2005 Aug; 133(8):903-10. PubMed ID: 16163428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates.
    Igari J; Oguri T; Higuchi T
    Jpn J Antibiot; 1994 Aug; 47(8):1013-29. PubMed ID: 7933531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.
    Wiedemann B; Jansen A
    J Antimicrob Chemother; 1990 Jul; 26(1):71-9. PubMed ID: 2211449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.
    Holt HA; Bywater MJ; Reeves DS
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():7-12. PubMed ID: 2292533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.
    Rolston KV; Messer M; Nguyen H; Ho D; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):581-5. PubMed ID: 1915401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial activities of sulbactam/ampicillin against clinically isolated microbial strains].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1995 Apr; 48(4):529-47. PubMed ID: 7783316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.